Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
NEOG's Cash to Debt is ranked higher than
97% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.06 vs. NEOG: No Debt )
Ranked among companies with meaningful Cash to Debt only.
NEOG' s Cash to Debt Range Over the Past 10 Years
Min: 0.15  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.89
NEOG's Equity to Asset is ranked higher than
91% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. NEOG: 0.89 )
Ranked among companies with meaningful Equity to Asset only.
NEOG' s Equity to Asset Range Over the Past 10 Years
Min: 0.72  Med: 0.88 Max: 0.93
Current: 0.89
0.72
0.93
Interest Coverage No Debt
NEOG's Interest Coverage is ranked higher than
91% of the 93 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 166.12 vs. NEOG: No Debt )
Ranked among companies with meaningful Interest Coverage only.
NEOG' s Interest Coverage Range Over the Past 10 Years
Min: 42.56  Med: 10000.00 Max: 9999.99
Current: No Debt
42.56
9999.99
F-Score: 4
Z-Score: 26.99
M-Score: -2.48
WACC vs ROIC
15.15%
14.99%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 18.67
NEOG's Operating margin (%) is ranked higher than
89% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.66 vs. NEOG: 18.67 )
Ranked among companies with meaningful Operating margin (%) only.
NEOG' s Operating margin (%) Range Over the Past 10 Years
Min: 15.68  Med: 17.96 Max: 20.75
Current: 18.67
15.68
20.75
Net-margin (%) 11.69
NEOG's Net-margin (%) is ranked higher than
85% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.98 vs. NEOG: 11.69 )
Ranked among companies with meaningful Net-margin (%) only.
NEOG' s Net-margin (%) Range Over the Past 10 Years
Min: 10.59  Med: 11.83 Max: 13.23
Current: 11.69
10.59
13.23
ROE (%) 10.02
NEOG's ROE (%) is ranked higher than
72% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.39 vs. NEOG: 10.02 )
Ranked among companies with meaningful ROE (%) only.
NEOG' s ROE (%) Range Over the Past 10 Years
Min: 9.97  Med: 11.60 Max: 13.38
Current: 10.02
9.97
13.38
ROA (%) 8.93
NEOG's ROA (%) is ranked higher than
86% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.60 vs. NEOG: 8.93 )
Ranked among companies with meaningful ROA (%) only.
NEOG' s ROA (%) Range Over the Past 10 Years
Min: 8.86  Med: 10.18 Max: 11.42
Current: 8.93
8.86
11.42
ROC (Joel Greenblatt) (%) 40.58
NEOG's ROC (Joel Greenblatt) (%) is ranked higher than
80% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.03 vs. NEOG: 40.58 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NEOG' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 33.35  Med: 38.98 Max: 52.57
Current: 40.58
33.35
52.57
Revenue Growth (3Y)(%) 13.90
NEOG's Revenue Growth (3Y)(%) is ranked higher than
75% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.70 vs. NEOG: 13.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NEOG' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -3  Med: 14.60 Max: 26.3
Current: 13.9
-3
26.3
EBITDA Growth (3Y)(%) 15.30
NEOG's EBITDA Growth (3Y)(%) is ranked higher than
76% of the 99 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.90 vs. NEOG: 15.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NEOG' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 2.6  Med: 19.30 Max: 40.6
Current: 15.3
2.6
40.6
EPS Growth (3Y)(%) 12.70
NEOG's EPS Growth (3Y)(%) is ranked higher than
72% of the 110 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.10 vs. NEOG: 12.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NEOG' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 5.6  Med: 16.45 Max: 27.4
Current: 12.7
5.6
27.4
» NEOG's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

NEOG Guru Trades in Q1 2015

Jim Simons 9,100 sh (New)
Mario Gabelli 16,500 sh (unchged)
Manning & Napier Advisors, Inc 42,745 sh (-11.98%)
Ron Baron 152,000 sh (-65.89%)
» More
Q2 2015

NEOG Guru Trades in Q2 2015

Jim Simons 48,600 sh (+434.07%)
Ron Baron 445,596 sh (+193.16%)
Mario Gabelli 16,500 sh (unchged)
Manning & Napier Advisors, Inc Sold Out
» More
Q3 2015

NEOG Guru Trades in Q3 2015

Jim Simons 272,743 sh (+461.20%)
Mario Gabelli 16,500 sh (unchged)
Ron Baron 444,596 sh (-0.22%)
» More
Q4 2015

NEOG Guru Trades in Q4 2015

Mario Gabelli 16,500 sh (unchged)
Jim Simons 125,100 sh (-54.13%)
» More
» Details

Insider Trades

Latest Guru Trades with NEOG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 50.29
NEOG's P/E(ttm) is ranked lower than
74% of the 150 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 28.35 vs. NEOG: 50.29 )
Ranked among companies with meaningful P/E(ttm) only.
NEOG' s P/E(ttm) Range Over the Past 10 Years
Min: 20.76  Med: 36.00 Max: 67.65
Current: 50.29
20.76
67.65
Forward P/E 38.31
NEOG's Forward P/E is ranked lower than
86% of the 117 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.92 vs. NEOG: 38.31 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 50.29
NEOG's PE(NRI) is ranked lower than
75% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.50 vs. NEOG: 50.29 )
Ranked among companies with meaningful PE(NRI) only.
NEOG' s PE(NRI) Range Over the Past 10 Years
Min: 20.11  Med: 36.07 Max: 67.83
Current: 50.29
20.11
67.83
P/B 4.65
NEOG's P/B is ranked lower than
79% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.50 vs. NEOG: 4.65 )
Ranked among companies with meaningful P/B only.
NEOG' s P/B Range Over the Past 10 Years
Min: 1.92  Med: 3.90 Max: 6.61
Current: 4.65
1.92
6.61
P/S 5.91
NEOG's P/S is ranked lower than
90% of the 243 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.21 vs. NEOG: 5.91 )
Ranked among companies with meaningful P/S only.
NEOG' s P/S Range Over the Past 10 Years
Min: 1.96  Med: 4.41 Max: 8.35
Current: 5.91
1.96
8.35
PFCF 63.01
NEOG's PFCF is ranked lower than
79% of the 132 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.05 vs. NEOG: 63.01 )
Ranked among companies with meaningful PFCF only.
NEOG' s PFCF Range Over the Past 10 Years
Min: 19.7  Med: 53.73 Max: 375.57
Current: 63.01
19.7
375.57
POCF 43.39
NEOG's POCF is ranked lower than
80% of the 154 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.46 vs. NEOG: 43.39 )
Ranked among companies with meaningful POCF only.
NEOG' s POCF Range Over the Past 10 Years
Min: 14.78  Med: 37.68 Max: 73.21
Current: 43.39
14.78
73.21
EV-to-EBIT 29.31
NEOG's EV-to-EBIT is ranked lower than
66% of the 176 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.84 vs. NEOG: 29.31 )
Ranked among companies with meaningful EV-to-EBIT only.
NEOG' s EV-to-EBIT Range Over the Past 10 Years
Min: 13.2  Med: 23.55 Max: 43.4
Current: 29.31
13.2
43.4
EV-to-EBITDA 24.44
NEOG's EV-to-EBITDA is ranked lower than
80% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 14.36 vs. NEOG: 24.44 )
Ranked among companies with meaningful EV-to-EBITDA only.
NEOG' s EV-to-EBITDA Range Over the Past 10 Years
Min: 10.9  Med: 20.00 Max: 36.2
Current: 24.44
10.9
36.2
PEG 4.38
NEOG's PEG is ranked lower than
71% of the 42 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.71 vs. NEOG: 4.38 )
Ranked among companies with meaningful PEG only.
NEOG' s PEG Range Over the Past 10 Years
Min: 0.94  Med: 2.22 Max: 6.03
Current: 4.38
0.94
6.03
Shiller P/E 77.45
NEOG's Shiller P/E is ranked lower than
88% of the 50 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 37.56 vs. NEOG: 77.45 )
Ranked among companies with meaningful Shiller P/E only.
NEOG' s Shiller P/E Range Over the Past 10 Years
Min: 34.63  Med: 65.46 Max: 108.23
Current: 77.45
34.63
108.23
Current Ratio 8.02
NEOG's Current Ratio is ranked higher than
85% of the 191 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.68 vs. NEOG: 8.02 )
Ranked among companies with meaningful Current Ratio only.
NEOG' s Current Ratio Range Over the Past 10 Years
Min: 3.19  Med: 6.47 Max: 14.54
Current: 8.02
3.19
14.54
Quick Ratio 6.05
NEOG's Quick Ratio is ranked higher than
81% of the 191 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.41 vs. NEOG: 6.05 )
Ranked among companies with meaningful Quick Ratio only.
NEOG' s Quick Ratio Range Over the Past 10 Years
Min: 1.78  Med: 4.37 Max: 10.77
Current: 6.05
1.78
10.77
Days Inventory 131.62
NEOG's Days Inventory is ranked lower than
68% of the 153 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 88.26 vs. NEOG: 131.62 )
Ranked among companies with meaningful Days Inventory only.
NEOG' s Days Inventory Range Over the Past 10 Years
Min: 130.81  Med: 148.88 Max: 182.11
Current: 131.62
130.81
182.11
Days Sales Outstanding 69.74
NEOG's Days Sales Outstanding is ranked lower than
54% of the 155 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.71 vs. NEOG: 69.74 )
Ranked among companies with meaningful Days Sales Outstanding only.
NEOG' s Days Sales Outstanding Range Over the Past 10 Years
Min: 60.52  Med: 69.90 Max: 76.57
Current: 69.74
60.52
76.57
Days Payable 49.00
NEOG's Days Payable is ranked lower than
54% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 52.88 vs. NEOG: 49.00 )
Ranked among companies with meaningful Days Payable only.
NEOG' s Days Payable Range Over the Past 10 Years
Min: 24.07  Med: 37.73 Max: 48.27
Current: 49
24.07
48.27

Valuation & Return

vs
industry
vs
history
Price/Net Cash 23.51
NEOG's Price/Net Cash is ranked lower than
80% of the 98 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.33 vs. NEOG: 23.51 )
Ranked among companies with meaningful Price/Net Cash only.
NEOG' s Price/Net Cash Range Over the Past 10 Years
Min: 3.89  Med: 31.38 Max: 194.8
Current: 23.51
3.89
194.8
Price/Net Current Asset Value 8.74
NEOG's Price/Net Current Asset Value is ranked lower than
57% of the 168 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.56 vs. NEOG: 8.74 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
NEOG' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.95  Med: 7.00 Max: 17.26
Current: 8.74
1.95
17.26
Price/Tangible Book 6.55
NEOG's Price/Tangible Book is ranked lower than
62% of the 214 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.88 vs. NEOG: 6.55 )
Ranked among companies with meaningful Price/Tangible Book only.
NEOG' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.58  Med: 4.80 Max: 9.8
Current: 6.55
1.58
9.8
Price/Projected FCF 3.07
NEOG's Price/Projected FCF is ranked lower than
73% of the 111 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.92 vs. NEOG: 3.07 )
Ranked among companies with meaningful Price/Projected FCF only.
NEOG' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.99  Med: 2.34 Max: 4.25
Current: 3.07
0.99
4.25
Price/DCF (Earnings Based) 2.17
NEOG's Price/DCF (Earnings Based) is ranked lower than
57% of the 30 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.86 vs. NEOG: 2.17 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.34
NEOG's Price/Median PS Value is ranked lower than
80% of the 239 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.94 vs. NEOG: 1.34 )
Ranked among companies with meaningful Price/Median PS Value only.
NEOG' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.31  Med: 0.70 Max: 1.9
Current: 1.34
0.31
1.9
Price/Peter Lynch Fair Value 4.59
NEOG's Price/Peter Lynch Fair Value is ranked lower than
100% of the 39 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.19 vs. NEOG: 4.59 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
NEOG' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.44  Med: 1.83 Max: 5.74
Current: 4.59
0.44
5.74
Price/Graham Number 3.82
NEOG's Price/Graham Number is ranked lower than
69% of the 136 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.53 vs. NEOG: 3.82 )
Ranked among companies with meaningful Price/Graham Number only.
NEOG' s Price/Graham Number Range Over the Past 10 Years
Min: 0.91  Med: 2.43 Max: 5.43
Current: 3.82
0.91
5.43
Earnings Yield (Greenblatt) (%) 3.46
NEOG's Earnings Yield (Greenblatt) (%) is ranked higher than
62% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. NEOG: 3.46 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
NEOG' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 2.3  Med: 4.25 Max: 7.6
Current: 3.46
2.3
7.6
Forward Rate of Return (Yacktman) (%) 11.95
NEOG's Forward Rate of Return (Yacktman) (%) is ranked higher than
54% of the 57 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 11.03 vs. NEOG: 11.95 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
NEOG' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 6.7  Med: 17.20 Max: 24
Current: 11.95
6.7
24

More Statistics

Revenue(Mil) $301
EPS $ 0.94
Beta1.77
Short Percentage of Float5.55%
52-Week Range $41.51 - 62.70
Shares Outstanding(Mil)37.44

Analyst Estimate

May16 May17
Revenue(Mil) 303 343
EPS($) 1.06 1.24
EPS without NRI($) 1.06 1.24

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:NG2.Germany,
Neogen Corp was formed as a Michigan corporation in June 1981 and actual operations began in 1982. The Company and subsidiaries develop, manufacture and market a diverse line of products dedicated to food and animal safety. The Company's food safety segment consists of diagnostic test kits and complementary products sold to food producers and processors to detect dangerous and/or unintended substances in human food and animal feed, such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, drug residues, pesticide residues and general sanitation concerns. These products are marketed by company sales personnel in North America, the United Kingdom and other parts of Europe, Mexico and Brazil and by distributors through the rest of the world. The majority of the tests are disposable, single-use, immunoassay and DNA detection products that rely on the Company's proprietary antibodies and RNA and DNA testing methodologies to produce rapid and accurate test results. The Company's expanding line of food safety products also includes bioluminescence-based diagnostic technology. It operates in two primary business areas: the Food Safety segment, which develops and markets products for the detection of pathogens, natural toxins, allergens and other unwanted substances in food and feed products; and the Animal Safety segment, which develops and markets products and services dedicated to animal health. The products of food safety segment consist of diagnostic test kits and complementary products marketed to food and feed producers and processors to detect dangerous and/or unintended substances in food and animal feed, such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, drug residues, pesticide residues and general sanitation concerns. Animal Safety's NeogenVet product line provides value-added products to the veterinary market. Top NeogenVet products include PanaKare, a digestive aid that serves as a replacement therapy where digestion of protein, carbohydrate and fat is inadequate due to exocrine pancreatic insufficiency; Natural Vitamin E-AD, which aids in the prevention and treatment of vitamin deficiencies in swine, cattle and sheep; and RenaKare, a supplement for potassium deficiency in cats and dogs. It manufactures its products in Lansing, Michigan; Lexington, Kentucky; Randolph, Wisconsin and Ayr, Scotland. The Company competes on the basis of ease of use, speed, accuracy and other similar performance characteristics of its products. It is subject to substantial governmental regulation.
» More Articles for NEOG

Headlines

Articles On GuruFocus.com
Buffett-Munger Model Portfolio Outperforms Again - June Model Portfolio Performance Update Jun 05 2012 
Focusing on Predictable Companies, Value Strategies Continue to Outperform. Apr 02 2012 
The Most Overpaid and Underpaid CEOs Jan 19 2012 
Value Idea Contest Results Announcement Apr 12 2012 
Neogen: Food and Animal Safety Supplier Serves Long-Term Investors Well Oct 03 2011 
Neogen Corp. (NEOG) President & COO Lon M Bohannon sells 15,000 Shares Mar 04 2011 
Neogen Corp. (NEOG) President & COO Lon M Bohannon sells 5,000 Shares Mar 01 2011 
Neogen Corp. (NEOG) Chairman & CEO James L Herbert sells 11,641 Shares Feb 17 2011 
Neogen Corp. (NEOG) President & COO Lon M Bohannon sells 5,000 Shares Feb 01 2011 
Neogen Corp. (NEOG) President & COO Lon M Bohannon sells 5,000 Shares Jan 21 2011 

More From Other Websites
Why Are Insiders Getting Rid of These 3 Stocks? Feb 02 2016
Today's Top 5 Stock Picks: Positioning for a Bounce Jan 21 2016
NEOGEN CORP Financials Jan 14 2016
NEOGEN CORP Files SEC form 10-Q, Quarterly Report Jan 08 2016
Neogen’s new Ramik® Green AG controls pests in field applications Jan 05 2016
Neogen Corp. Earnings Analysis: Q2, 2016 By the Numbers Jan 04 2016
Neogen Corp. breached its 50 day moving average in a Bearish Manner : January 1, 2016 Jan 01 2016
NEOGEN CORP Files SEC form 8-K, Completion of Acquisition or Disposition of Assets Dec 30 2015
Neogen (NEOG) Acquires Rodenticide Assets of Virbac Corp Dec 24 2015
Neogen acquires rodenticide assets Dec 23 2015
Neogen acquires rodenticide assets Dec 23 2015
NEOGEN CORP Files SEC form 8-K, Results of Operations and Financial Condition Dec 22 2015
Neogen (NEOG) Q2 Earnings Up Y/Y on Revenue Improvement Dec 22 2015
Edited Transcript of NEOG earnings conference call or presentation 21-Dec-15 4:00pm GMT Dec 21 2015
Neogen reports 16% increase in net income Dec 21 2015
Neogen misses 2Q profit forecasts Dec 21 2015
Neogen misses 2Q profit forecasts Dec 21 2015
Neogen reports 16% increase in net income Dec 21 2015
Q2 2016 Neogen Corp Earnings Release - Before Market Open Dec 21 2015
Take Profits In Neogen Ahead of Second-Quarter Earnings Dec 18 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK